FDA-approved
Bones & muscles
Abaloparatide
Evidence
FDA approved
Class
Parathyroid hormone-related peptide analog
KEY TAKEAWAY
Abaloparatide is a synthetic analog of parathyroid hormone-related protein approved for postmenopausal women with osteoporosis at high risk of fracture.
Written by the Veylo editorial team · Updated
November 2026
What it is
A bone-building analog of PTHrP
Approved for
Postmenopausal osteoporosis at high fracture risk
Key fact
Reduced vertebral and non-vertebral fractures in a large trial
Route
Daily injection
Evidence strength
FDA approved
Abaloparatide, sold as Tymlos, is a 34-amino-acid peptide modeled on parathyroid hormone-related protein.
It activates the PTH1 receptor in a way that favors bone formation over bone breakdown.
The FDA approved abaloparatide in 2017 for postmenopausal women with osteoporosis at high fracture risk.
Treatment of postmenopausal osteoporosis in women at high risk of fracture.
Dizziness, nausea, palpitations and a drop in blood pressure on standing are most common. Raised calcium can also occur.
Miller PD et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis. JAMA. 2016;316:722-733.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.